Nexus Investment Management ULC Increases Position in Gilead Sciences, Inc. $GILD

Nexus Investment Management ULC boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 8.9% during the third quarter, HoldingsChannel.com reports. The firm owned 259,024 shares of the biopharmaceutical company’s stock after purchasing an additional 21,220 shares during the period. Gilead Sciences makes up approximately 4.1% of Nexus Investment Management ULC’s holdings, making the stock its 11th largest holding. Nexus Investment Management ULC’s holdings in Gilead Sciences were worth $28,752,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Norges Bank purchased a new position in shares of Gilead Sciences during the 2nd quarter valued at approximately $2,150,268,000. Ameriprise Financial Inc. raised its position in Gilead Sciences by 397.6% during the second quarter. Ameriprise Financial Inc. now owns 6,748,403 shares of the biopharmaceutical company’s stock worth $748,147,000 after acquiring an additional 5,392,191 shares during the period. Invesco Ltd. lifted its holdings in Gilead Sciences by 33.5% during the second quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock valued at $1,499,098,000 after purchasing an additional 3,394,330 shares in the last quarter. Assenagon Asset Management S.A. grew its position in shares of Gilead Sciences by 164.4% in the third quarter. Assenagon Asset Management S.A. now owns 3,489,062 shares of the biopharmaceutical company’s stock valued at $387,286,000 after purchasing an additional 2,169,266 shares during the period. Finally, Kingstone Capital Partners Texas LLC acquired a new stake in shares of Gilead Sciences in the second quarter valued at about $238,083,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on GILD shares. TD Cowen raised their price target on shares of Gilead Sciences from $115.00 to $125.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. Sanford C. Bernstein set a $135.00 target price on Gilead Sciences and gave the company an “outperform” rating in a report on Monday, December 29th. Argus lifted their price target on Gilead Sciences from $130.00 to $135.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. Cantor Fitzgerald restated an “overweight” rating and issued a $135.00 price objective on shares of Gilead Sciences in a report on Friday, October 31st. Finally, Rothschild & Co Redburn upped their target price on shares of Gilead Sciences from $143.00 to $153.00 in a report on Monday, November 10th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $133.20.

Insiders Place Their Bets

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction dated Tuesday, October 28th. The stock was sold at an average price of $119.39, for a total transaction of $1,193,900.00. Following the sale, the chief executive officer owned 581,203 shares in the company, valued at $69,389,826.17. This represents a 1.69% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $122.00, for a total value of $366,000.00. Following the completion of the transaction, the chief financial officer owned 153,503 shares of the company’s stock, valued at $18,727,366. The trade was a 1.92% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 136,257 shares of company stock valued at $16,855,192. Corporate insiders own 0.27% of the company’s stock.

Gilead Sciences Stock Up 0.4%

Shares of NASDAQ GILD opened at $121.10 on Monday. Gilead Sciences, Inc. has a 1 year low of $88.57 and a 1 year high of $128.70. The company has a market capitalization of $150.25 billion, a P/E ratio of 18.78, a P/E/G ratio of 0.64 and a beta of 0.33. The company has a 50 day simple moving average of $123.27 and a 200-day simple moving average of $117.67. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. The business had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The company’s revenue was up 3.0% compared to the same quarter last year. During the same period in the prior year, the business posted $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, equities research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th were given a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.6%. The ex-dividend date of this dividend was Monday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is currently 48.99%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.